Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(5):e33133.
doi: 10.1371/journal.pone.0033133. Epub 2012 May 7.

Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope

Affiliations

Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope

Hiroshi Furukawa et al. PLoS One. 2012.

Abstract

Introduction: Interstitial Lung Disease (ILD) is frequently associated with Rheumatoid Arthritis (RA) as one of extra-articular manifestations. Many studies for Human Leukocyte Antigen (HLA) allelic association with RA have been reported, but few have been validated in an RA subpopulation with ILD. In this study, we investigated the association of HLA class II alleles with ILD in RA.

Methods: An association study was conducted on HLA-DRB1, DQB1, and DPB1 in 450 Japanese RA patients that were or were not diagnosed with ILD, based on the findings of computed tomography images of the chest.

Results: Unexpectedly, HLA-DRB1*04 (corrected P [Pc] = 0.0054, odds ratio [OR] 0.57), shared epitope (SE) (P = 0.0055, OR 0.66) and DQB1*04 (Pc = 0.0036, OR 0.57) were associated with significantly decreased risk of ILD. In contrast, DRB1*16 (Pc = 0.0372, OR 15.21), DR2 serological group (DRB1*15 and *16 alleles) (P = 0.0020, OR 1.75) and DQB1*06 (Pc = 0.0333, OR 1.57, respectively) were significantly associated with risk of ILD.

Conclusion: HLA-DRB1 SE was associated with reduced, while DR2 serological group (DRB1*15 and *16) with increased, risk for ILD in Japanese patients with RA.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal’s policy and have the following conflicts: The following funders are supported in whole or in part by the subsequent pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

References

    1. Perricone C, Ceccarelli F, Valesini G. Autoimmun Rev 10: 599–608. Epub 2011 Apr 2022; 2011. An overview on the genetic of rheumatoid arthritis: a never-ending story. - PubMed
    1. Scott IC, Steer S, Lewis CM, Cope AP. Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis. Best Pract Res Clin Rheumatol. 2011;25:447–468. - PubMed
    1. Lewis SN, Nsoesie E, Weeks C, Qiao D, Zhang L. Prediction of disease and phenotype associations from genome-wide association studies. PLoS ONE 6: e27175. Epub 22011 Nov. 2011;27174 - PMC - PubMed
    1. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol. 1998;10:187–200. - PubMed
    1. Turesson C, Weyand CM, Matteson EL. Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations? Arthritis Rheum. 2004;51:853–863. - PubMed

Publication types

MeSH terms

LinkOut - more resources